Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for...
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
Skyrizi sales surpass Humira for the first time in Q3 2024, with Skyrizi sales up 50.8% to $3.205 billion and Humira down 37.2% to $2.227 billion. This shift is attributed to the rise of Skyrizi and Rinvoq, impacting adalimumab biosimilar market share despite their growth.
Representation of Native Hawaiian and Pacific Islander Individuals in Clinical Trials
Native Hawaiian and Pacific Islander participation in clinical trials for top-selling drugs in 2024 was either unknown or minimal, with 60% of trials not reporting their numbers. All trials that did report had fewer participants than their population proportion, highlighting the need for purposeful strategies to include these groups, such as establishing recruitment sites in areas like Hawai‘i.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath